



Published in final edited form as:

Fam Cancer. 2009 ; 8(4): 451–456. doi:10.1007/s10689-009-9264-6.

Younger Age-at-Diagnosis for Familial Malignant Testicular Germ Cell Tumor

Phuong L. Mai¹, Bingshu E. Chen², Kathy Tucker³, Michael Friedlander³, Kelly-Anne Phillips⁴, David Hogg⁵, Michael A.S. Jewett⁵, Istvan Bodrogi⁶, Lajos Geczi⁶, Edith Olah⁶, Ketil Heimdal⁷, Sophie D. Fossa⁷, Katherine L. Nathanson⁸, Larissa Korde¹, Douglas F Easton⁹, Darshna Dudakia¹⁰, Robert Huddart¹¹, Michael R. Stratton¹⁰, D. Timothy Bishop¹², Elizabeth A. Rapley¹⁰, and Mark H. Greene¹

¹ Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Rockville, Maryland 20852, USA

² NCIC, Clinical Trials Group, Queen's University, 10 Stuart Street, Kingston, Ontario K7L 3N6, Canada

³ Dept of Medical Oncology, Division of Medicine, University of New South Wales and Prince of Wales Hospital, Randwick, NSW 2031, Australia

⁴ Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, St Andrew's Place, East Melbourne, Victoria 3002, Australia

⁵ Princess Margaret Hospital and University of Toronto, 610 University Ave, Toronto, ON, M5G 2M9, Canada

⁶ Department of Chemotherapy and Department of Molecular Genetics, National Institute of Oncology, Rath Gyorgy u. 7-9, H-1122 Budapest, Hungary

⁷ Departments of Clinical Cancer Research and Medical Genetics, Rikshospitalet-Radiumhospitalet University Hospital, NO-0027, Oslo, Norway

⁸ Division of Medical Genetics, Department of Medicine, 351 BRB 2/3, 421 Curie Blvd. University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA

⁹ CRC Genetic Epidemiology Unit, Strangeways Research Laboratory, Worts Causeway, Cambridge CB1 8RN, UK

¹⁰ Section of Cancer Genetics, Institute of Cancer Research, Brookes Lawley Building, Sutton, Surrey SM2 5NG, UK

¹¹ Academic Radiotherapy Unit, Institute of Cancer Research, 15 Cotswold Rd, Belmont Sutton, Surrey SM2 5NG, UK

¹² Imperial Cancer Research Fund Genetic Epidemiology Lab, Ashley Wing, St. James's University Hospital, Beckett Street, Leeds, LS9 7TF UK

Abstract

One of the clinical hallmarks of hereditary cancer susceptibility disorders is a younger-than-usual age at diagnosis. Familial aggregation of testicular germ cell tumor (TGCT) has been reported, but data on whether familial TGCT cases are diagnosed at an earlier age are inconclusive. Here we

Corresponding author: Phuong L. Mai, MD, MS, 6120 Executive Blvd EPS/7022, Rockville, MD 20852, Phone: 301 496-9928, Fax: 301 496 1854, maip@mail.nih.gov.

The authors have no conflict of interest or financial disclosures to report.

compared the age at diagnosis of familial TGCT cases with that of population cases in several countries. Familial TGCT is defined as affected individuals from families with ≥ 2 cases of TGCT. Age at diagnosis of familial cases from the United States, Canada, United Kingdom, Australia and New Zealand, Norway, and Hungary was compared to cases identified in population-based cancer registries from the respective country, using the Generalized Estimation Equation (GEE) method. Age at diagnosis was statistically significantly younger for familial TGCT cases from North America ($p=0.024$), the United Kingdom ($p<0.0001$), and Australia and New Zealand ($p=0.0033$) compared with population cases. When stratified by histology, the difference in age at diagnosis distribution between familial and population cases was observed for seminoma cases from North America ($p=0.002$) and the United Kingdom ($p<0.0001$) and nonseminoma cases from the United Kingdom ($p=0.029$) and Australia and New Zealand ($p=0.0023$). In summary, we found that the age at diagnosis for familial TGCT cases is, on the average, 2–3 years younger than that for the population cases in North America, United Kingdom, and Australia and New Zealand. The younger age at diagnosis might be suggestive of a genetic basis for familial TGCT.

Keywords

age at diagnosis; familial; non-seminoma; population-based testicular cancer; seminoma; testicular germ cell tumor

Introduction

Testicular germ cell tumor (TGCT) is the most common malignancy in males ages 15–45. The age-standardized annual incidence rate worldwide is approximately 1.5/100,000, with substantial variations between countries [1]. Family history is among the few established risk factors for TGCT [2,3]. Although genetic susceptibility has been implicated in familial TGCT [4–6], no high-penetrance susceptibility locus has been identified. Recent genome-wide linkage studies suggested that multiple genes, each with modest effects, contribute to TGCT susceptibility [7,8].

Based on Knudson's two-hit theory of carcinogenesis [9], one of the main features of single-trait gene hereditary cancers is an earlier age-at-diagnosis [10]; however, it is less clear if familial cancers not associated with a single-gene trait are also diagnosed at an earlier age. Reports on familial TGCT age-at-diagnosis have been conflicting [4,11–14]; however, most of the data were from small series. Moreover, the clinicopathologic characteristics of familial TGCT have not been shown to be different from sporadic cases [13–15].

Histologically, TGCT is classified into seminoma and non-seminoma. The average age-at-diagnosis for seminoma is in the fourth decade of life, about 7–8 years older than non-seminoma [3,14,16,17]. To investigate whether familial TGCT cases are diagnosed at a younger-than-usual age, we compared them with population cases in North America (United States and Canada), United Kingdom, Australia and New Zealand, Norway, and Hungary.

Materials and Methods

Familial Cases

Familial TGCT cases were previously ascertained through the International Testicular Cancer Linkage Consortium (ITCLC) [7,18]. Briefly, participants were from families with ≥ 2 confirmed cases of invasive TGCT or a combination of TGCT and extragonadal germ cell tumor, and with DNA available from at least one case. Participants were enrolled in protocols approved by the participating centers' Institutional Review Boards and provided informed consent for use of their genetic, demographic, and family history data. Information on deceased

family members was provided by their next-of-kin or study participants. Eligibility and clinical data were ascertained by enrolling centers using pathology reports, medical records, death certificate, or participant's report. For this analysis, we included countries contributing ≥ 25 cases with non-missing histology and age-at-diagnosis to the ITCLC. Cases from the United States and Canada were combined to form the "North America" group. Cases from England and Ireland were combined, as were cases from Australia and New Zealand. We analyzed all cases together and by tumor histology (seminoma and non-seminoma). Cases with missing histology were included in the overall analysis, but excluded from the analyses by histology.

Population Cases

Population cases were identified from population-based cancer registries for the respective countries. Using the International Classification of Diseases for Oncology, ICD-O-3, coding scheme, we included cases with topography code of C62.0–C62.9 and the following morphology codes: 9061, 9062, and 9063 (seminoma); 9065, 9070, 9071, 9080, 9081, 9082, 9102, 9084, 9085, 9100, 9101, 9083 (non-seminoma); cases with a morphology code of 9064 (germinoma) were included in the overall analysis, but excluded in the analyses by histology.

Statistical Analysis

The age-at-diagnosis distributions for familial and population TGCT by countries/regions were estimated using the kernel density method [19]. Differences in age-at-diagnosis for familial and population TGCT, overall and stratified by histology, were evaluated using the Generalized Estimation Equation [20], which takes the within family correlation of age-at-onset into account. Interactions between the difference in age-at-diagnosis between familial and population TGCT and geographical location were tested using the Generalized Linear Model [21].

Results

A total of 817 familial TGCT cases and 62,817 population cases from North America, the United Kingdom, Norway, Australia and New Zealand, and Hungary were included (Table). Familial and population TGCT age-at-diagnosis distribution curves for each country/region are shown in the Figure.

North America

The mean age-at-diagnosis was 2 years younger for familial TGCT compared with population cases (95% CI = -3.7, -0.3, $p=0.024$). When examined by histology, familial seminoma cases were diagnosed 3.2 years younger than population seminoma cases (95% CI = -5.2, -1.2, $p=0.002$). Familial non-seminoma cases were also younger at diagnosis than population cases, but the difference was not statistically significant (-0.9, 95% CI = -2.8, 0.9, $p=0.33$).

United Kingdom

Compared with population cases, the age-at-diagnosis was 3.1 years younger (95% CI = -4.0, -2.1, $p<0.0001$) for all familial TGCT cases, 3.0 years younger (95% CI = -4.3, -1.8, $p<0.0001$) for familial seminoma cases, and 1.5 years younger (95% CI = -2.9, -0.2, $p=0.029$) for familial non-seminoma cases.

Australia/New Zealand

Age-at-diagnosis was reported in 5-year age groups in the Australian Tumor Registry; consequently, the median age-at-diagnosis for population cases was imputed, assuming equal distribution of cases for each age within an age group. Overall, familial TGCT cases were diagnosed 3.5 years younger than population cases (95% CI = -5.9, -1.2, $p=0.0033$). Familial

non-seminoma cases were diagnosed at a younger age than population cases (-2.8 , 95% CI = -5.2 , -0.4 , $p=0.0023$). No difference in age-at-diagnosis was observed for seminoma.

Norway

The age-at-diagnosis for familial TGCT cases was younger than that of population cases; however, the difference was not statistically significant, either for all cases (-2.4 , 95% CI = -5.3 , 0.3 , $p=0.10$) or when stratified by histology (-2.8 , 95% CI = -6.6 , 0.9 , $p=0.14$ for seminoma; -2.3 , 95% CI = -5.2 , 0.6 , $p=0.12$ for non-seminoma).

Hungary

Familial TGCT cases were not statistically significantly younger than population cases (-1.7 , 95% CI = -4.9 , 1.6 , $p=0.31$). When examined by histology, familial seminoma cases had a statistically non-significant 1.7 years younger age-at-diagnosis compared with population cases (95% CI = -8.4 , 5.1 , $p = 0.63$). There was no evidence of a younger age-at-diagnosis for familial non-seminoma (1.1 , 95% CI = -3.1 , 5.3 , $p=0.61$).

There was no evidence of interaction between regions/countries and the difference in age-at-diagnosis for familial cases and population cases, either overall ($p=.78$), or when stratified by histology ($p= 0.99$ for seminoma and $p=0.82$ for nonseminoma).

Discussion

From this large international collection of familial TGCT cases, we observed that familial cases, on average, were diagnosed 2–3 years younger than population cases, with seminoma demonstrating a larger difference. Moreover, the younger age-at-diagnosis among familial cases is observed in the U.S. and Canada, the United Kingdom, and Australia and New Zealand, with no evidence of a differential effect by geographical locations. Although familial TGCT cases were diagnosed at a younger age than population cases in Norway and Hungary, these differences did not reach statistical significant levels, likely because of the small number of familial cases enrolled.

Previously reported data on age-at-diagnosis of familial TGCT are inconsistent; while some studies suggested that familial TGCT was diagnosed about 3 to 5 years earlier than sporadic cases [4,11], which is similar to our findings, others did not show any differences [12–14]. However, most of these studies were small series with limited numbers of familial cases. Our study compared a large number of familial TGCT cases to unselected population cases from several countries. Because the mean age-at-diagnosis for TGCT varies by country/geographical region, we compared familial cases from each region to the corresponding population-based cancer registry.

Earlier screening for breast, colorectal, and prostate cancer may be recommended for those with a family history of early diagnosis of the same cancer [22]. Although we observed a statistically significant younger age-at-diagnosis for familial TGCT, it is unclear if this difference is clinically meaningful. Currently, there are no standard screening recommendations for TGCT, either in the general population or among individuals at increased risk. Thus, our finding, though may be suggestive of a genetic basis for familial TGCT, is unlikely to alter health care recommendations for individuals with a family history of TGCT.

This study has several strengths. First, this is the largest group of familial TGCT cases with age-at-diagnosis reported to date. Second, we compared familial TGCT from each region/country with cases from the respective population-based cancer registries, thus eliminating the effect of differences in TGCT age-at-diagnosis by geographical locations. Furthermore, despite the variations in mean age-at-diagnosis of TGCT by country, the earlier age-at-diagnosis for

familial TGCT was consistently observed across all regions/countries examined. Lastly, we were able to examine seminoma and non-seminoma separately, which is important given known differences in average age-at-diagnoses by histology.

This report also has some potential limitations. Clinicopathologic data for familial cases was obtained from multiple sources; thus, the age-at-diagnosis might not have been accurate in cases where pathology reports were not available. Additionally, study participants were either referred by their healthcare providers or self-referred to one of the study centers in response to advertisement. It is possible that families/cases with earlier age-at-diagnosis were more likely to participate in the ITCLC.

In summary, in this international, multicenter study, we observed a younger age-at-diagnosis for familial TGCT cases compared with population cases obtained from cancer registries across all regions/countries examined. This finding is suggestive of a genetic basis for familial TGCT, though further studies are needed.

Acknowledgments

We would like to thank Dr. Parry Guilford for his contribution to the familial TGCT cases. We also thank Istvan Gaudi (Cancer Registry of National Institute of Oncology, Budapest, Hungary) and Sue Westlake (Social & Health Analysis & Reporting Division, Office for National Statistics, UK) for their contribution from the cancer registries. This research was funded in part by the Intramural Research Program of the National Cancer Institute, National Institutes of Health, and supported by contracts N02-CP-11019 and N02-CP-65504 with Westat, Incorporated.

Abbreviations

ITCLC	International Testicular Cancer Linkage Consortium
TGCT	testicular germ cell tumor

References

1. Ferlay, J.; Bray, F.; Pisani, P., et al. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. Lyon: IARC ; 2004. Press
2. Hemminki K, Sundquist J, Bermejo JL. Familial risks for cancer as the basis for evidence-based clinical referral and counseling. *Oncologist* 2008;13:239–247. [PubMed: 18378534]
3. Holzik MFL, Rapley EA, Hoekstra HJ, et al. Genetic predisposition to testicular germ-cell tumours. *Lancet Oncol* 2004;5:363–371. [PubMed: 15172357]
4. Nicholson PW, Harland SJ. Inheritance and testicular cancer. *Br J Cancer* 1995;71:421–426. [PubMed: 7841065]
5. Heimdal K, Olsson H, Tretli S, et al. A segregation analysis of testicular cancer based on Norwegian and Swedish families. *Br J Cancer* 1997;75:1084–1087. [PubMed: 9083348]
6. Harland SJ, Daugaard G, Horwich A, et al. The familial influence on bilateral testicular germ cell cancer: Medical Research Council study TER2. Annual Meeting Proceedings. *J Clin Oncol* 2006;24 Abstract no. 4590.
7. Crockford GP, Linger R, Hockley S, et al. Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. *Hum Mol Genet* 2006;15:443–451. [PubMed: 16407372]
8. Rapley EA, Crockford GP, Easton DF, et al. Localisation of susceptibility genes for familial testicular germ cell tumour. *APMIS* 2003;111:128–135. [PubMed: 12752252]
9. Knudson AG Jr. Hereditary cancer, oncogenes, and antioncogenes. *Cancer Res* 1985;45:1437–1443. [PubMed: 2983882]
10. Lindor NM, McMaster ML, Lindor CJ, et al. Concise handbook of familial cancer susceptibility syndromes - Second edition. *J Natl Cancer Inst Monogr* 2008;2008:3–93.

11. Forman D, Oliver RT, Brett AR, et al. Familial testicular cancer: a report of the UK family register, estimation of risk and an HLA class 1 sib-pair analysis. *Br J Cancer* 1992;65:255–262. [PubMed: 1739626]
12. Dieckmann K-P, Pichlmeier U. The prevalence of familial testicular cancer. *Cancer* 1997;80:1954–1960. [PubMed: 9366298]
13. Sonneveld DJA, Sleijfer DT, Schraffordt Koops H, et al. Familial testicular cancer in a single-centre population. *Eur J Cancer* 1999;35:1368–1373. [PubMed: 10658529]
14. Dong C, Lonnstedt I, Hemminki K. Familial testicular cancer and second primary cancers in testicular cancer patients by histological type. *Eur J Cancer* 2001;37:1878–1885. [PubMed: 11576844]
15. Mai PL, Friedlander M, Tucker K, et al. The International Testicular Cancer Linkage Consortium: A clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. *Urol Oncol*. 2009
16. Sokoloff MH, Joyce GF, Wise M. Testis cancer. *J Urol* 2007;177:2030–2041. [PubMed: 17509283]
17. Fossa SD, Chen J, Schonfeld SJ, et al. Risk of contralateral testicular cancer: A population-based study of 29 515 U.S. men. *J Natl Cancer Inst* 2005;97:1056–1066. [PubMed: 16030303]
18. The International Testicular Cancer Linkage Consortium. Candidate regions for testicular cancer susceptibility genes. *APMIS* 1998;106:64–72. [PubMed: 9524563]
19. Parzen E. On estimation of a probability density function and mode. *Ann Math Stat* 1962;33:1065–1076.
20. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. *Biometrika* 1986;73:13–22.
21. McCullagh, P.; Nelder, JA. *Generalized Linear Models*. 2. London: Chapman and Hall/CRC; 1989.
22. Smith RA, Cokkinides V, Brawley OW. Cancer Screening in the United States, 2008: a review of current American Cancer Society guidelines and cancer screening issues. *CA Cancer J Clin* 2008;58:161–179. [PubMed: 18443206]




Figure. Kernel density curves for familial and population testicular germ cell tumor cases in North America, United Kingdom, Australia and New Zealand, Norway, and Hungary

Table

Number of familial and population testicular germ cell tumor cases by regions/countries

Regions/Countries	Familial			Population [†]		Mean Age Differences (95%CI) p-value
	Number	Age at Diagnosis Median (range)	Number	Age at Diagnosis Median(range)	Number	
North America	All	188	31 (14–82)	24446	33 (0–92)	-2.0 (-3.7, -0.3), p=0.024
	Seminoma	59	34 (20–58)	13591	36 (12–92)	-3.2 (-5.2, -1.2), p=0.0017
	Non-seminoma	94	26 (14–56)	10550	28 (0–90)	-0.9 (-2.8, 0.9), p=0.33
United Kingdom	All	480	32 (2–87)	20211	35 (0–95)	-3.1 (-4.0, -2.1), p<0.0001
	Seminoma	212	35 (20–65)	12450	37 (12–93)	-3.0 (-4.3, -1.8), p<0.0001
	Non-seminoma	188	27 (2–66)	7517	30 (0–95)	-1.5 (-2.9, -0.2), p=0.029
Norway	All	65	30 (16–72)	6541	33 (15–95)	-2.4 (-5.3, 0.3), p=0.10
	Seminoma	36	33 (24–72)	3611	37 (15–95)	-2.8 (-6.6, 0.9), p=0.14
	Non-seminoma	27	28 (16–45)	2930	28 (15–88)	-2.3 (-5.2, 0.6), p=0.119
Australia and New Zealand	All	54	31 (19–62)	10374	34 (0–90) [*]	-3.5(-5.9, -1.2) p=0.0033
	Seminoma	31	31 (20–62)	6690	35 (10–90)	-3.2(-6.5, 0.1) p=0.059
	Non-seminoma	22	30 (19–43)	3684	29 (0–90)	-2.8(-5.2, -0.4) p=0.023
Hungary	All	30	31 (20–55)	1245	32 (0–87)	-1.69 (-4.9, 1.6), p=0.31
	Seminoma	9	36 (20–55)	693	35 (17–87)	-1.7 (-8.4, 5.1), p = 0.63
	Non-seminoma	10	28.5 (21–42)	552	28 (0–75)	1.1 (-3.1, 5.3), p=0.61

[†] Population cases for North America: SEER-17, 1973–2003; United Kingdom: Office of National Statistics, 1990–2004; Norway: Cancer Registry of Norway, 1953–2005; Australia and New Zealand: Australian Tumor Registry, 1982–2003; and Hungary: Hungarian Cancer Registry, 2001–2006.

^{*} Age at diagnosis for population cases were reported in 5-year age groups. Individual age at diagnosis is obtained using imputation method